Evaluated antigen Immunologicalassay Mainresults Rseferences
PPD, ESAT-6, 85B IFN-g-producing cells (ELISPOT); cytokines (chemiluminescence) Increased number of PPD-specific IFN-g-producing cells and higher IL-2, IL-12, IFN-g, CXCL9 and CXCL10 levels in TB-IRIS patients compared to baseline and to non-IRIS individuals [18]
PPD, ESAT-6 IFN-g-producing cells (ELISPOT) Increased number of PPD-specific IFN-g-producing cells during IRIS (two out of three patients), compared to baseline. No IFN-g response to ESAT-6 antigen [30]
PGL-Tb1, ESAT-6, CFP10 Antibodies (ELISA) Similar anti-ESAT-6/CFP10 and anti-ManLAM antibody levels in TB-IRIS and non-IRIS individuals [21]
PPD, ESAT-6, 38kD, Acr 1 e 2 IFN-g-producing cells (ELISPOT) Increased number of ESAT-6 and PPD-specific IFN-g-producing cells in TB-IRIS patients compared to non-IRIS individuals [20]
PPD IFN-gproducing cells (ELISPOT); (ICC, flow cytometry) Increased number of PPD-specific IFN-g-producing cells in TB-IRIS patients compared to non-IRIS. Multifunctional (IFN-g+TNF-a+IL-2-) CD4+ T-cells [22]
RD1, PPD IFN-g level (IGRA) Similar IFN-g levels between pTB-IRIS and non-IRIS patients. Increased IFN-g levels in uTB-IRIS patients compared to controls [31]
RD1 e PPD IFN-g level (IGRA); IL-2 and IL-12 (ELISA) Increased IFN-g levels to PPD during IRIS compared to baseline. Similar IFN-g, IL-2 and IL-12 levels in TB-IRIS patients compared to non-IRIS individuals [32]
PPD IFN-g level (IGRA); IL-5 (ELISA) Similar IFN-g and IL-5 levels in TB-IRIS patients and non-IRIS individuals [33]
Mtb H37Rv, PPD Cytokines (RT-PCR and ELISA) Increase quantity of cytokines transcripts (IL1-b, IL-5, IL-6, IL-10, IL-13, IL-17a, IFN-g, GM-CSF and TNF) and of IL-12p40, IL-1b, GM-CSF, TNF, IL-10, IL-6, IL-2 and IL-8 levels in TB-IRIS patients compared to non-IRIS individuals [23]
PPD e Lipomannan IFN-g-producing cells (ELISPOT); cytokines (ELISA) Increase number of PPD-specific IFN-g-producing cells and of TFN levels in response to lipomannan Mtb antigen in TB-IRIS patients compared to non-IRIS individuals [35]
PPD IFN-g-producing cells
(ICC, flow cytometry)
Increased frequency of PPD-specific IL-2, IL-10 and TNF-producing CD4+ T-cells following resolution of IRIS [25]
ESAT-6, 38 kD, Acr 1 e 2, PPD e MtbH37Rv IFN-g-producing cells (ELISPOT); cytokines
(flow cytometry)
Similar frequency of specific IFN-g-producing cells among TB-IRIS groups (TB-MDR, TB-RM and TB-FS). Higher IFN-g/IL-10 and L-2/IL-10 ratios in TB-IRIS FS compared to TB-IRIS MDR and TB-IRIS RM [26]
PPD e RD1 Cytokines
(flow cytometry)
Increased of CXCL10 levels in TB-IRIS patients compared to no-IRIS individuals [36]
PPD, ESAT-6, CFP10 IFN-g-producing cells
(ICC, flow cytometry)
Higher frequency of PPD-specific IFN-g+CD4+, IFN-g+TNF+CD4+, IFN-g+CD8+and TNF+CD8+ T-cells in TB-IRIS patients compared to non-IRIS individuals [28]
PPD, ESAT-6. CFP10 IFN-g-producing cells (ELISPOT); cytokines
(flow cytometry)
Similar number of specific IFN-g-producing cells among TB-IRIS patients and non-IRIS individuals [29]
pIRIS: tuberculosis associated with paradoxical IRIS; uIRIS: tuberculosis associated with unmasking IRIS; non-IRIS: patients without IRIS; ELISPOT: Enzyme Linked Immunospot Assay; PPD: Purified Protein Derivative; ESAT-6: Early Secretory Antigenic Target-6; RD1: Region of Difference 1; PGL-Tb1: Glycolipid Antigen of Mtb; ELISA: Enzyme Linked Immunosorbent Assay; IGRA: Interferon Gamma Release Assay; ICC: Intracellular Cytokines; RT-PCR: Reverse Transcription Polymerase Chain Reaction. TB-MDR: Tuberculosis Multi-Drug Resistant; TB-RM: Tuberculosis Rifampicin Mono-Resistant; TB-FS: Tuberculosis Fully Sensitive.
Table 2: Evaluation of the immune response to Mycobacterium tuberculosis antigens in patients with TB-IRIS.